Report Overview:
The global key manufacturers of Promethazine Hydrochloride Injection include Sanofi, Pfizer, Hikma Pharmaceuticals, Southwest Pharmaceutical, Tianjin Jinyao Group, Jinling Pharmaceutical, Guangdong Southland Pharmaceutical, Shanghai Harvest Pharmaceutical and Advacare Pharma, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Promethazine Hydrochloride Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Promethazine Hydrochloride Injection. This report contains market size and forecasts of Promethazine Hydrochloride Injection in global, including the following market information:
Market Value:
The global Promethazine Hydrochloride Injection market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
CAGR of XX% (2022 – 2029)
By Types:
•Intravenous Drip •Intramuscular Injection
By Applications:
Hospital
Clinics
Key players include:
•Sanofi
•Pfizer
•Hikma Pharmaceuticals
•Southwest Pharmaceutical
•Tianjin Jinyao Group
•Jinling Pharmaceutical
•Guangdong Southland Pharmaceutical
•Shanghai Harvest Pharmaceutical
